{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:35:51Z","timestamp":1784039751498,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:00:00Z","timestamp":1497571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:00:00Z","timestamp":1497571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/bcj.2017.49","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T16:15:45Z","timestamp":1497629745000},"page":"e571-e571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit"],"prefix":"10.1038","volume":"7","author":[{"given":"M A","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Roussou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D C","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Panagiotidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Psimenou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Marinaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Bacharaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Mparmparoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Matsouka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Giannouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,16]]},"reference":[{"key":"BFbcj201749_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014; 25: 195\u2013200.","journal-title":"Ann Oncol"},{"key":"BFbcj201749_CR2","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 2016; 34: 1544\u20131557.","journal-title":"J Clin Oncol"},{"key":"BFbcj201749_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/17474086.2016.1210003","volume":"9","author":"D Fotiou","year":"2016","unstructured":"Fotiou D, Dimopoulos MA, Kastritis E . Managing renal complications in multiple myeloma. Expert Rev Hematol 2016; 9: 839\u2013850.","journal-title":"Expert Rev Hematol"},{"key":"BFbcj201749_CR4","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x","volume":"91","author":"R Torra","year":"1995","unstructured":"Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854\u2013859.","journal-title":"Br J Haematol"},{"key":"BFbcj201749_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","volume":"65","author":"LM Knudsen","year":"2000","unstructured":"Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175\u2013181.","journal-title":"Eur J Haematol"},{"key":"BFbcj201749_CR6","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","volume":"150","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Dixon D . Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693\u20131695.","journal-title":"Arch Intern Med"},{"key":"BFbcj201749_CR7","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blade","year":"1998","unstructured":"Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889\u20131893.","journal-title":"Arch Intern Med"},{"key":"BFbcj201749_CR8","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1038\/bcj.2016.17","volume":"6","author":"M Laforet","year":"2016","unstructured":"Laforet M, Jourde-Chiche N, Haddad F, Sallee M, Stoppa AM, Brunet P et al. Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014. Blood Cancer J 2016; 6: e409.","journal-title":"Blood Cancer J"},{"key":"BFbcj201749_CR9","unstructured":"Cook M, Hutchison C, Fifer L, Gillmore J, Heyne N, Weisel K et al. High cut-off haemodialysis(HCO-HD) does not improve outcomes in myeloma cast nephropathy: results of European trial of Free Light Chain removal extended haemodialysis in cast nephropathy (EULITE). EHA 2016, Abstract P270."},{"key":"BFbcj201749_CR10","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood.V128.22.978.978","volume":"128","author":"F Bridoux","year":"2016","unstructured":"Bridoux F, Pegourie B, Augeul-Meunier K, Royer B, Joly B, Lamy T et al. Treatment of myeloma cast nephropathy (MCN): a randomized trial comparing intensive haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a bortezomib-based regimen (the MYRE Study, by the Intergroupe Francophone du My\u00e9lome (IFM) and the French Society of Nephrology (SFNDT)). Blood 2016; 128: 978\u2013978.","journal-title":"Blood"},{"key":"BFbcj201749_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbcj201749_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3324\/haematol.10759","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546\u2013549.","journal-title":"Haematologica"},{"key":"BFbcj201749_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1124\/jpet.108.142604","volume":"327","author":"R Sarkozi","year":"2008","unstructured":"Sarkozi R, Perco P, Hochegger K, Enrich J, Wiesinger M, Pirklbauer M et al. Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther 2008; 327: 645\u2013656.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFbcj201749_CR14","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 2015; 33: 2863\u20132869.","journal-title":"J Clin Oncol"},{"key":"BFbcj201749_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3324\/haematol.2016.145078","volume":"102","author":"E Kastritis","year":"2016","unstructured":"Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E et al. Evaluation of the revised international staging system (R-ISS) in an independent cohort of unselected patients with multiple myeloma. Haematologica 2016; 102: 593\u2013599.","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201749.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201749","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bcj.2017.49","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201749.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:28:04Z","timestamp":1671730084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,16]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["BFbcj201749"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.49","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,16]]},"assertion":[{"value":"16 June 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EK: Genesis Pharma, Takeda, Janssen Amgen, Prothena; ET: BMS, Janssen, Celgene, Takeda Genesis Pharma, Amgen, Novartis and MAD: Novartis, Janssen, Celgene, Takeda, BMS, Amgen. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}